Therapy of Advanced Non–Small-Cell Lung Cancer with Irinotecan and Gemcitabine in Combination

Jemal, 2002, Cancer statistics, 2002, CA Cancer J Clin, 52, 23, 10.3322/canjclin.52.1.23 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group, BMJ, 311, 899, 10.1136/bmj.311.7010.899 Georgoulias, 2001, Platinum-based and non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial, Lancet, 357, 1478, 10.1016/S0140-6736(00)04644-4 Cullen, 1999, Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life, J Clin Oncol, 17, 3188, 10.1200/JCO.1999.17.10.3188 Ranson, 2000, Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 92, 1074, 10.1093/jnci/92.13.1074 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Wozniak, 1998, Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study, J Clin Oncol, 16, 2459, 10.1200/JCO.1998.16.7.2459 Sandler, 2000, Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 18, 122, 10.1200/JCO.2000.18.1.122 Bonomi, 2000, Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial, J Clin Oncol, 18, 623, 10.1200/JCO.2000.18.3.623 Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Van Meerbeeck, 2001, A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 20, 308a Scagliotti, 2001, Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer, Proc Am Soc Clin Oncol, 20, 308a Sederholm, 2002, Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group, Semin Oncol, 29, 50, 10.1053/sonc.2002.34276 Lilenbaum, 2002, Single-agent (SA) versus combination therapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomizd trial of efficacy, quality of life (QOL), and cost-effectiveness, Proc Am Soc Clin Onc, 21, 1a Georgoulias, 2002, Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 21, 291a Kosmidis, 2002, Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial, J Clin Oncol, 20, 3578, 10.1200/JCO.2002.12.112 Dancey, 1996, Current perspectives on camptothecins in cancer treatment, Br J Cancer, 74, 327, 10.1038/bjc.1996.362 Baker, 1997, Phase II study of irinotecan (CPT-11) in advanced nonsmall cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 16, 461a Fukuoka, 1985, [Phase II study of cis-dichlorodiammineplatinum (II) for non-small cell lung cancer], Gan To Kagaku Ryoho, 12, 471 Negoro, 1991, Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-smallcell lung cancer, J Natl Cancer Inst, 83, 1164, 10.1093/jnci/83.16.1164 Negoro, 1991, [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group], Gan To Kagaku Ryoho, 18, 1013 Douillard, 1995, A phase II study of CPT-11 (irinotecan) in non small cell lung, Proc Am Soc Clin Oncol, 14, 365 Niho, 1999, Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 18, 492a Masuda, 1999, Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study, Proc Am Soc Clin Oncol, 18, 459a Plunkett, 1995, Preclinical characteristics of gemcitabine, Anticancer Drugs, 6, 7, 10.1097/00001813-199512006-00002 Le Chevalier, 1997, Single-agent gemcitabine in non-small cell lung cancer: the French experience, Semin Oncol, 24, S7 Perng, 1997, Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study, J Clin Oncol, 15, 2097, 10.1200/JCO.1997.15.5.2097 Bahadori, 1999, Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines, Anticancer Res, 19, 5423 Fujita, 2002, [Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice], Gan To Kagaku Ryoho, 29, 577 O'Reilly, 2000, Combination gemcitabine and irinotecan in advanced solid-tumor malignancies: Preliminary results of a phase I trial, Cancer Conference Highlights, 4, 11 Alberts, 2001, Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks, Ann Oncol, 12, 627, 10.1023/A:1011140818150 Mulcahy, 2002, Phase I trial of CPT-11 and gemcitabine in solid tumors, Proc Am Soc Clin Oncol, 21, 87b Rocha Lima, 1999, Phase I study of CPT-11 and gemcitabine in patients with solid tumors, Cancer Therapeutics, 2, 58 Kakolyris, 2002, A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy, Anticancer Res, 22, 1891 Nishio, 2002, Phase I study of biweekly chemotherapy with gemcitabine (gem) and irinotecan (CPT-11) in previously treated patients (pts) with non-small-cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 21, 219b Kouroussis, 2002, Second-line treatment with irinotecan (CPT-11) and gemcitabine (GEM) versus CPT-11 in patients with advanced NSCLC preteated with taxanes and displatinum: Preliminary results of a multicenter randomized phase II study, Proc Am Soc Clin Oncol, 21, 304a Rocha Lima, 2002, CALGB 39809: randomized phase II trial of gemcitabine/irinotecan and gemcitabine/docetaxel in stage IIIB (malignant pleural effusion) or stave IV NSCLC, Proc Am Soc Clin Oncol, 21, 337a